Thu, Jul 31, 2014, 7:44 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • clemcaldwell clemcaldwell Feb 17, 2013 5:22 PM Flag

    GDC-0973: Phase III started 02/11/2013

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: GDC-0973, RG7421 (formerly XL518)
    Found at BioCentury website

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Every time I see a post on GDC 0973, I think back to Ohad Hammers article. More specifically this paragraph-

      "Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche."


      Sentiment: Strong Buy

    • I hope Exelixis gets a milestone for this.

      Sentiment: Strong Buy

4.03-0.24(-5.62%)Jul 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.